The Big Picture

Imagine needing brain surgery. Today, this often means multiple operations, a fully opened skull, and weeks in the hospital. NeuroOne (NMTC) is changing this with new technology that lets doctors treat patients through a tiny hole, in a single hospital visit, right at their bedside.

What Makes NeuroOne Special?

1. They make super-thin electrodes (like tiny wires) that doctors use in brain surgery

2. Their devices are 90% thinner than what's used today

3. Most importantly, their newest product (OneRF) can both find and treat problem areas in the brain using the same device

Strong Partnership

Zimmer Biomet, a $25 billion medical device company, sells NeuroOne's products. They just expanded their partnership and paid NeuroOne $3 million upfront for rights to sell the new OneRF system. This is huge validation from an industry leader.

The Market Opportunity

• About 50,000 Americans each year need this kind of treatment for epilepsy

• Current methods are so invasive that only 5,000 actually get surgery

• NeuroOne's simpler approach could help many more patients say yes to treatment

• Each procedure brings in about $5,000 in revenue

Beyond Epilepsy

NeuroOne's technology could also help with:

• Chronic pain treatment ($2.3 billion market)

• Delivering drugs directly to the brain ($7 billion market by 2025)

• Parkinson's disease treatment ($3.4 billion market by 2033)

The Numbers

• Current stock price: Around $1

• Market value: About $25 million

• Revenue growing 100% year over year

• Need about $5 million more to reach breakeven

• Recently raised $2.65 million and got $3 million from Zimmer

Why It's Interesting Now